Skip to main content
Premium Trial:

Request an Annual Quote

Aragen Bioscience Inks License with Cevec

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Aragen Bioscience has licensed the rights to use Cevec Pharmaceuticals' CAP-T protein production technology in its custom recombinant cell line offerings, CEVEC said today.

The license gives Aragen the rights to offer its research clients custom recombinant human cell lines that express biotherapeutic proteins and antibodies using the Cevec technology, which is based on CAP cells, a cell line used for stable protein production.

These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture, and they include human-like post-translational modifications.

"We believe that human cells will be a superior production system for a variety of complex proteins," Aragen Bioscience CEO Rick Srigley said in a statement. "Cevec's technology is a valuable addition to our existing expression portfolio and will enable our customers to pursue new directions for proteins that were difficult in the past or did not show satisfactory post-translational modifications."

Financial terms of the agreement were not released.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.